George Sarah J, Baker Andrew H
Bristol Heart Institute, Bristol Royal Infirmary, UK.
Mol Biotechnol. 2002 Oct;22(2):153-64. doi: 10.1385/MB:22:2:153.
Cardiovascular diseases are a major cause of fatality, disability, and economic burden in Western civilization. Although the pharmaceutical industry has delivered a plethora of drugs for treatment of diverse cardiovascular complaints, there remain many conditions for which pharmacological regimens are either nonexistent or largely ineffective. In contrast, remarkable progress has been made in the field of vascular gene transfer in the last decade. The vast majority of studies are preclinical, although a number of high profile vascular gene therapy clinical trials are in progress. In principle, vascular gene therapy represents an unprecedented opportunity to treat a host of cardiovascular diseases in humans although many scientific, clinical, and ethical obstacles remain. Here we discuss the rapid progress in preclinical vascular gene therapy, highlight the most appropriate gene delivery vectors, and discuss the advances toward the ultimate goal of an efficient and safe gene therapy for diverse cardiovascular diseases.
心血管疾病是西方文明中导致死亡、残疾和经济负担的主要原因。尽管制药行业已提供了大量药物用于治疗各种心血管疾病，但仍有许多病症不存在有效的药物治疗方案或药物治疗效果甚微。相比之下，在过去十年中，血管基因转移领域取得了显著进展。尽管多项备受瞩目的血管基因治疗临床试验正在进行，但绝大多数研究仍处于临床前阶段。原则上，血管基因治疗为治疗人类多种心血管疾病提供了前所未有的机会，尽管仍存在许多科学、临床和伦理障碍。在此，我们将讨论临床前血管基因治疗的快速进展，重点介绍最合适的基因传递载体，并探讨在实现针对各种心血管疾病的高效安全基因治疗这一最终目标方面所取得的进展。
